Arcutis Biotherapeutics, Inc.

NasdaqGS:ARQT 株式レポート

時価総額：US$2.6b

Arcutis Biotherapeutics 配当と自社株買い

配当金 基準チェック /06

Arcutis Biotherapeutics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.3%

バイバック利回り

総株主利回り-0.3%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

ナラティブの更新 • May 18

ARQT: Q4 Execution And 2026 Revenue Guidance Will Support Further Upside

Analysts have nudged the blended price target on Arcutis Biotherapeutics slightly lower to about $34.63 from $34.75. This reflects modest tweaks to revenue growth, profit margin and P/E assumptions following recent Q4 driven model updates across the Street.
Seeking Alpha • May 15

Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound

Summary Arcutis Biotherapeutics (ARQT) is evolving into a specialized dermatology platform, leveraging ZORYVE's expanding indications, formulations, and prescriber base for compounding revenue growth. ARQT reported Q1 2026 net revenues of $105.4M (up 65% YoY), reaffirmed 2026 revenue guidance of $480–495M, and demonstrated a significant reduction in net loss with strong gross margins. ZORYVE's pediatric and primary care expansion, new product launches, and pipeline progress support ARQT’s strategy to capture a larger share of the chronic dermatology market. Despite premium valuation multiples, ARQT’s rapid revenue growth, positive operating cash flow, and commercial momentum justify a bullish outlook, contingent on continued execution and market penetration. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 21

ARQT: Raised 2026 Revenue Outlook And Q4 Performance Will Drive Further Upside

Analysts now cluster around a $35 price target for Arcutis Biotherapeutics, reflecting only a small shift of a few dollars from prior targets as recent Q4 results, updated revenue guidance, and ongoing commercialization progress for Zoryve are incorporated into refreshed models. Analyst Commentary Recent Street research converges around a $35 price target, with modest adjustments on either side as analysts refresh models following Q4 results, updated guidance, and ongoing Zoryve commercialization.
ナラティブの更新 • Apr 07

ARQT: Higher 2026 Revenue Guidance And Q4 Execution Will Support Upside

Analysts now converge around a $35 price target for Arcutis Biotherapeutics, reflecting updated models following the Q4 report, revised revenue guidance, and ongoing assessments of Zoryve commercialization efforts. Analyst Commentary Recent Street research shows a tight cluster of targets around $35, with several firms updating their models after the Q4 report and revised guidance.
ナラティブの更新 • Mar 24

ARQT: Strong Q4 Execution And Higher 2026 Guidance Will Support Confidence

Narrative Update The consensus analyst price target for Arcutis Biotherapeutics is now $35, reflecting modest model updates following the Q4 report, stronger than expected sales, higher revenue guidance, and a continued focus on maximizing the value of Zoryve. Analyst Commentary Recent research highlights a cluster of price targets around $35, with analysts updating their models after the Q4 report, revisions to revenue guidance, and continued emphasis on the Zoryve franchise.
ナラティブの更新 • Mar 10

ARQT: Infant Data And Steroid Concerns Will Support Higher Confidence In Guidance

The analyst price target for Arcutis Biotherapeutics has been raised by $3, from $31.75 to $34.75, as analysts update their models following the Q4 report, higher management guidance, and ongoing confidence in Zoryve commercialization and revenue trajectory. Analyst Commentary Recent Street research on Arcutis Biotherapeutics clusters tightly around a US$35 price target, with most firms updating their models after the Q4 report and new management guidance.
ナラティブの更新 • Feb 23

ARQT: Infant Data And Steroid Concerns Will Support Future Upside Potential

Analysts kept their price target for Arcutis Biotherapeutics steady at $31.75, citing only minor adjustments to assumptions for discount rate, revenue growth, profit margin, and future P/E to reflect updated views on the company’s risk profile and earnings potential. What's in the News Reported positive topline Phase 2 INTEGUMENT-INFANT data for ZORYVE cream 0.05% in 101 infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis, with low rates of adverse events, all mild to moderate, and no serious adverse events (Key Developments).
ナラティブの更新 • Feb 08

ARQT: Infant Atopic Dermatitis Data Will Drive Future Upside Potential

Analysts have nudged their price target for Arcutis Biotherapeutics higher to US$31.75 from US$30.86, tying the change to updated fair value estimates, a slightly adjusted discount rate, and modest tweaks to long term revenue growth, profit margin, and future P/E assumptions. What's in the News Positive topline results from the INTEGUMENT-INFANT Phase 2 study of ZORYVE cream 0.05% in 101 infants with mild to moderate atopic dermatitis, with a low incidence of mild to moderate adverse events and 58% of participants reaching EASI-75 at Week 4 (company announcement).
ナラティブの更新 • Jan 25

ARQT: Pediatric Dermatology Pipeline And 2026 Revenue Guide Will Support Upside

Analysts have trimmed their price targets for Arcutis Biotherapeutics by about $1 to roughly $31, citing updated assumptions around fair value, discount rate, profit margin, and future P/E that slightly adjust their overall outlook. What's in the News FDA accepted a supplemental New Drug Application for ZORYVE cream 0.3% to extend plaque psoriasis treatment to children aged 2 to 5 years, with a PDUFA target action date of June 29, 2026 (Company announcement).
ナラティブの更新 • Jan 11

ARQT: Pediatric Dermatology Expansion And 2026 Revenue Outlook Will Support Upside

Analysts now see Arcutis Biotherapeutics' fair value at US$31.63 per share, with the latest price target grounded in updated assumptions around the discount rate, revenue growth, profit margins, and future P/E that remain broadly consistent with prior estimates. What's in the News The FDA accepted a supplemental New Drug Application for ZORYVE cream 0.3% to expand its plaque psoriasis indication to children aged 2 to 5 years, with a PDUFA target action date of June 29, 2026, supported by MUSE and long term safety studies in this age group (company announcement).
ナラティブの更新 • Dec 21

ARQT: Pediatric Dermatology Expansion Will Support Stronger Long-Term Earnings Power

Analysts have modestly raised their price target on Arcutis Biotherapeutics by updating key valuation inputs, including a slightly higher discount rate and future earnings multiple. This results in a new implied fair value of 31.63 dollars per share that remains unchanged from prior estimates but is now underpinned by refined growth and margin assumptions.
分析記事 • Dec 09

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Despite an already strong run, Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) shares have been powering on, with a gain...
ナラティブの更新 • Dec 06

ARQT: Pediatric Approvals And Long-Term Data Will Support Gradual Portfolio Expansion

Analysts have nudged their price target on Arcutis Biotherapeutics slightly higher, from 31 dollars to approximately 31 dollars and 63 cents, citing modest improvements in long term revenue growth, profit margin expectations, and valuation multiples. What's in the News FDA accepted a supplemental new drug application to extend ZORYVE cream 0.3 percent plaque psoriasis treatment to children aged 2 to 5, with a PDUFA target action date of June 29, 2026 (Company press release).
ナラティブの更新 • Nov 22

ARQT: Pediatric Launches And Recent Data Will Support Measured Progress Ahead

Analysts have maintained their price target for Arcutis Biotherapeutics at $31.00, citing stable growth estimates and consistent profit margin expectations. What's in the News The FDA accepted a supplemental New Drug Application (sNDA) for ZORYVE cream 0.3% to treat plaque psoriasis in children aged 2 to 5.
ナラティブの更新 • Nov 06

ARQT: Expanded Pediatric Launch And Profit Margin Improvements Will Drive Sentiment Higher

Narrative Update on Arcutis Biotherapeutics Analysts have raised their price target for Arcutis Biotherapeutics from $23.38 to $31.00 per share, citing improved profit margin outlook and a slightly lower discount rate as key factors behind the adjustment. What's in the News The FDA approved ZORYVE (roflumilast) cream 0.05% for mild to moderate atopic dermatitis in children aged 2 to 5, providing a steroid-free topical option for young patients (FDA approval).
分析記事 • Oct 31

Results: Arcutis Biotherapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit

Shareholders will be ecstatic, with their stake up 24% over the past week following Arcutis Biotherapeutics, Inc. 's...
ナラティブの更新 • Oct 23

Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises

Arcutis Biotherapeutics saw its analyst price target raised by $5. Analysts cited strong product sales, robust prescription growth, and promising opportunities for future indication expansion as key drivers behind the upward revision.
新しいナラティブ • Oct 20

Very Bullish

It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.
ナラティブの更新 • Oct 09

Chronic Skin Trends Will Boost Non-Steroidal Treatment Adoption

Analysts have raised their price target for Arcutis Biotherapeutics from $22.75 to $23.38. The decision was based on stronger-than-expected product sales, ongoing commercial execution, and promising potential for expanded indications, all of which support mid- and long-term growth.
分析記事 • Oct 02

Revenues Not Telling The Story For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) After Shares Rise 27%

Despite an already strong run, Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) shares have been powering on, with a gain...
ナラティブの更新 • Sep 18

Chronic Skin Trends Will Boost Non-Steroidal Treatment Adoption

Upward analyst revisions for Arcutis Biotherapeutics reflect stronger-than-expected product sales, accelerating prescription growth, and optimism over Zoryve’s potential broader indications, lifting the consensus price target from $21.86 to $22.75. Analyst Commentary Bullish analysts highlighted Arcutis's stronger-than-expected total product sales and robust 19% quarter-over-quarter prescription growth, with stable gross-to-net (GTN) in the 50% range.
分析記事 • Jul 15

Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • May 09

Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) defied analyst predictions to release its quarterly results, which were...
User avatar
新しいナラティブ • Apr 26

FDA PDUFA Date And Payer Expansion Will Unlock Opportunity

Expanding ZORYVE's indications and payer coverage is expected to significantly boost revenue and market potential.
Seeking Alpha • Apr 19

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets

Summary Arcutis Biotherapeutics is rated a buy with a $19 price target, driven by strong Zoryve sales, a solid balance sheet, and strategic CFO transition. CFO David Topper is stepping down, replaced by Latha Vairavan, whose expertise aligns better with Arcutis's current commercial stage and financial goals. Zoryve's performance exceeds expectations, with significant revenue growth and expanded Medicaid coverage, bolstered by a robust sales force. Key upcoming milestones include regulatory events for Zoryve and clinical readouts for ARQ-255 and ARQ-234, supporting continued growth and valuation. Read the full article on Seeking Alpha
Seeking Alpha • Mar 12

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute

Summary Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth ahead via indication expansion for lead product Zoryve. After taking partial profits, the stock still accounts for 7.5% of my Core Biotech portfolio. Zoryve currently has ~3% market share in approved indications and management thinks 15% or above is within the realm of possibility. Balance sheet remains solid, revenue growth is steady, and the stock is starting to appeal to generalist growth investors. I continue to hold my remaining shares patiently as I anticipate continued execution by management and revenue acceleration in the 2025 to 2026 timeframe. Read the full article on Seeking Alpha
分析記事 • Mar 09

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up

Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • Feb 26

Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations

Summary Arcutis Biotherapeutics is a strong buy due to ZORYVE's rapid sales growth and potential for positive earnings within 12 months. ZORYVE, a non-steroidal cream for psoriasis and dermatitis, saw Q4 sales of $69.4M, a 413% YoY increase, beating sales estimates by $10.8M. ZORYVE has maintained quarterly growth of >40% since Q1 2024. Remarkably only one additional quarter of such robust growth will bring sales to a pace needed to achieve profitability. I maintain a $21/share price target now within 12 months, driven by ZORYVE's growth and market disruption potential among traditional steroid treatments. Read the full article on Seeking Alpha
Seeking Alpha • Jan 23

Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period

Summary Arcutis Biotherapeutics, Inc. stock has surged 133% since January 2024 and over 60% since August due to impressive revenue growth, despite ongoing net losses and limited cash reserves. The company’s Zoryve topical cream products have shown strong prescription growth and improving margins, but the market cap of $1.6bn may be considered overvalued given current financials. Key developments in 2025 include potential FDA approvals, Medicaid and Medicare reimbursement expansions, and a co-promotion deal with Kowa Pharmaceuticals to boost market reach. Despite a strong product and potential for $500m annual sales, I downgrade ARQT shares to “Hold” due to competitive pressures, financial challenges, and expectations running a little too hot. Read the full article on Seeking Alpha
分析記事 • Jan 02

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

決済の安定と成長

配当データの取得

安定した配当: ARQTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: ARQTの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Arcutis Biotherapeutics 配当利回り対市場
ARQT 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (ARQT)n/a
市場下位25% (US)1.4%
市場トップ25% (US)4.2%
業界平均 (Biotechs)2.4%
アナリスト予想 (ARQT) (最長3年)0%

注目すべき配当: ARQTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: ARQTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: ARQTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: ARQTが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/27 04:11
終値2026/05/27 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Arcutis Biotherapeutics, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17

アナリスト機関
Richard J. LawGoldman Sachs
null nullGuggenheim Securities, LLC
Seamus FernandezGuggenheim Securities, LLC